Published in J Manag Care Pharm on June 01, 2012
The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res (2015) 1.07
Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient (2013) 0.94
Review of the cost of venous thromboembolism. Clinicoecon Outcomes Res (2015) 0.81
Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis. J Thromb Thrombolysis (2015) 0.75
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet (2011) 4.78
Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain (2004) 4.72
Instruments for evaluating education in evidence-based practice: a systematic review. JAMA (2006) 4.50
Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation (2012) 3.74
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol (2002) 3.05
Persistent nonmalignant pain and analgesic prescribing patterns in elderly nursing home residents. J Am Geriatr Soc (2004) 2.81
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics (2006) 2.66
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med (2003) 2.22
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med (2007) 2.20
Evidence-based risk communication: a systematic review. Ann Intern Med (2014) 2.14
Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer (2013) 2.10
Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm (2003) 2.09
Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost. J Med Econ (2014) 2.00
Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol (2006) 1.89
Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med (2010) 1.75
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia (2007) 1.70
Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension (2012) 1.65
Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. Neurology (2012) 1.62
The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD (2010) 1.59
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol (2011) 1.55
Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics (2007) 1.54
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer (2009) 1.54
Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest (2004) 1.53
Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion (2009) 1.53
Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. Pain Med (2010) 1.51
Detection of pulmonary emboli with 99mTc-labeled anti-D-dimer (DI-80B3)Fab' fragments (ThromboView). Am J Respir Crit Care Med (2011) 1.51
Topiramate titration to response: analysis of individualized therapy study (TRAITS). Ann Pharmacother (2003) 1.49
Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause (2015) 1.45
Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm (2005) 1.45
Dosing guidelines, not protocols, for managing warfarin therapy. Am J Health Syst Pharm (2010) 1.42
The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective. Dis Manag (2008) 1.38
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin (2014) 1.36
Long-term effects of analgesics in a population of elderly nursing home residents with persistent nonmalignant pain. J Gerontol A Biol Sci Med Sci (2006) 1.34
Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol (2009) 1.33
Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother (2008) 1.32
Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia (2008) 1.32
Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord (2006) 1.31
Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol (2010) 1.30
Congestive heart failure and QRS duration: establishing prognosis study. Chest (2002) 1.28
Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm (2009) 1.25
Factors that influence prescribing decisions. Ann Pharmacother (2004) 1.24
Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med (2011) 1.24
Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum (2005) 1.23
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer (2006) 1.20
Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int (2009) 1.17
Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study. Crit Care (2007) 1.14
The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol (2008) 1.13
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics (2015) 1.08
Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States. J Occup Environ Med (2008) 1.08
Comment on: editorial by Husted et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 781-782). Thromb Haemost (2014) 1.07
Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw (2005) 1.06
Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol (2007) 1.04
Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. Curr Med Res Opin (2008) 1.04
Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. Pharmacotherapy (2011) 1.03
Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause (2011) 1.03
Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy. Thromb J (2008) 1.03
Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother (2005) 1.02
Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics (2012) 1.02
Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care (2002) 1.00
Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion (2009) 0.99
Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther (2012) 0.98
Potential drug-drug interactions in the outpatient setting. Med Care (2006) 0.96
Changes in the USP heparin monograph and implications for clinicians. Pharmacotherapy (2010) 0.96
Outcomes and prognostic factors of systolic as compared with diastolic heart failure in urban America. Congest Heart Fail (2005) 0.96
Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol (2008) 0.95
Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. Ann Allergy Asthma Immunol (2012) 0.95
Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient (2013) 0.94
Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer (2013) 0.94
Adverse events involving intravenous patient-controlled analgesia. Am J Health Syst Pharm (2007) 0.93
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer (2011) 0.92
Anticoagulation management services: entering a new era. Pharmacotherapy (2010) 0.92
A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther (2002) 0.91
Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs. J Am Acad Dermatol (2006) 0.91
A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry (2005) 0.91
Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. Curr Med Res Opin (2009) 0.91
Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. J Med Econ (2014) 0.90
Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease. J Am Soc Nephrol (2006) 0.90
Predictors of unstable anticoagulation in African Americans. J Thromb Thrombolysis (2008) 0.90
Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. Epilepsy Behav (2011) 0.90
Rivaroxaban: practical considerations for ensuring safety and efficacy. Pharmacotherapy (2013) 0.90
Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl Health Econ Health Policy (2014) 0.90
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer (2008) 0.89
Cost burden and treatment patterns associated with management of heavy menstrual bleeding. J Womens Health (Larchmt) (2012) 0.89
Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm (2008) 0.89
Development and validation of a new instrument to evaluate the ease of use of patient-controlled analgesic modalities for postoperative patients. J Med Econ (2010) 0.89
Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry (2013) 0.88